Permanent Telemedicine Rules Build on COVID-Era Flexibilities
The U.S. Drug Enforcement Administration (DEA) has finalized new rules to make temporary telemedicine flexibilities introduced during the COVID-19 public health emergency permanent. These rules govern how controlled substances can be prescribed via telemedicine, balancing accessibility to care with safeguards against medication misuse. The new framework introduces special telemedicine registrations, national monitoring systems, and expanded patient protections. For more details, see the DEA’s official rulemaking announcement in the Federal Register.
Rules for Prescriptions Without In-Person Visits
The new regulations apply to telemedicine encounters where a patient has not been seen in person by the prescribing medical provider and is being prescribed controlled substances. Key points include:
- Providers may prescribe Schedule III-V drugs without an in-person visit if they hold a special DEA registration.
- Specialized medical providers, such as psychiatrists, hospice care physicians, and pediatricians, may prescribe Schedule II drugs via telemedicine under an advanced registration.
- Providers must maintain state telemedicine registrations for each state where they practice.
Once a patient has had an in-person visit with a provider, controlled substances can be prescribed via telemedicine indefinitely.
Expanded Access to Buprenorphine for Opioid Use Disorder
The rules allow patients to receive a 6-month supply of buprenorphine, a medication used to treat opioid use disorder, following a telemedicine consultation. Further prescriptions require an in-person visit with a medical provider. This flexibility aims to ensure uninterrupted access to critical treatments while maintaining oversight. Click here for more information.
Nationwide Prescription Drug Monitoring Program (PDMP)
The DEA will implement a national Prescription Drug Monitoring Program (PDMP) to provide pharmacists and healthcare providers visibility into a patient’s prescription history. This system will help track controlled substance prescriptions across all 50 states, improving safety and reducing misuse.
This initiative complements the new requirement for online telemedicine platforms to register with the DEA. These platforms, which connect patients with providers for controlled substance prescriptions, must comply with stricter standards to prevent unregulated prescribing practices.
Telemedicine Provisions for Veterans Affairs Patients
The DEA has exempted VA practitioners from special registration requirements in consultation with the U.S. Department of Veterans Affairs (VA). Once a VA patient has had an in-person medical examination by any VA provider, this relationship extends to all VA telemedicine providers. This rule ensures seamless continuity of care for veterans receiving treatment across the VA network. For more information, see the full text of this rule here.
Public Comments Invited on Additional Safeguards
The DEA is seeking public feedback to refine the regulations further. Key areas open for comment include:
- Additional specialists eligible to prescribe Schedule II medications.
- Whether telemedicine prescriptions should be restricted by state boundaries.
- Limits on the proportion of Schedule II prescriptions issued via telemedicine.
Public comments will guide the implementation timeline and may lead to further adjustments to these rules.
